BGB Group

A few weeks back, our incredible strategists Anka Gorgiev, PhD, Pooja Bhavsar, PhD, Miki Kim, and Stephanie Sloves hit the Fast Company Innovation Festival in NYC. We find that the most powerful inspiration exists beyond what we face every day in our industry. We're always looking for ways to explore outside of the expected to observe, listen, learn, discuss, challenge, ideate, all in an effort to apply exciting innovation to our client work. Click on our video below to learn more about what the team considered to be their 5 key takeaways. Oh... and, Ryan Reynolds, we'd rate your session a 10 ?? !! #inspired #innovators #ideators #futurefocused

Susannah Amiteye is one of our SCHEMA payer and market access experts focused on the rare disease space. We know that access and reimbursement remain a challenge and that there is a lot of work to be done! Last week she attended Global Genes RARE Advocacy Summit in Kansas City, Missouri with rare disease patients, caregivers, advocates, healthcare professionals, and researchers. Susannah connected with other participants on latest in rare disease innovations, best practices for advocating on an individual and organizational level, and actionable strategies to improve care and accelerate change. Reach out to us to learn more! #accessexperts #rarediseaseexperts

Earlier this month, our SVP Global Brand Strategy, Parrus Doshi attended the HIMSS AI in Healthcare Forum to chat with experts, and take in real-world examples of just how transformative AI is proving to be in our healthcare industry. Parrus came away with 7 key topics he found most relevant... from the role of AI in the patient experience, to how AI is reducing cognitive workload. Flip through to learn more about how we see these topics shaping our future! #experts #strategy

September is blood cancer awareness month. As oncology experts, our job takes us beyond spreading awareness. We feel it's important to come together and really think about the future this space deserves. How can we continue to show up for our brands and help push boundaries and expectations? We asked our heme onc experts one question..."Describe the future you're helping to build!" Check out what Eric Brandel, Christine Schwall-Pecci, PhD, Wanette Vargas Riad, Ph.D., Michelle Kean, Marly Doerr and Amanda Eckel had to say... We'd love to hear from YOU... How are you helping to support blood cancer awareness month?

What does it take to truly operate as an agile agency? A lot in fact... Agile has become quite the industry buzz word. But we know that in order to operate efficiently, quickly, and smartly it comes down to people, mindset, structure and products. Agility is our reality. Meet our team of experts including our certified scrum master Hans Riis, head of behavioral science and applied intelligence Harry Sharman ??, and the leadership team Simon Hackett, Kerri McLeod, Art Chavez, and Lila Shah-Wright who nourish our agile culture every day. View our teaser and click the link below to view the FULL CONVERSATION. https://rb.gy/4lo1wf

The BGB Group team is dialed into the excitement of Day 1 at ESMO - European Society for Medical Oncology 2024. This year is shaping up to be a little different...?In addition to the presidential symposia featuring practice-changing late phase clinical data, the society has added an additional presidential, titled “Eyes to the Future”, which will focus on novel concepts in cancer research and care from the application of artificial intelligence (AI) to new approaches to overcoming resistance mechanisms.?Reach out to us to learn more as we dive in to discover all of the trends at #ESMO 2024. #oncexperts #esmo2024 #futureofoncology

This time next week, BGB Group and our Kx Advisors colleagues will be packing up and heading to the?2024 European Society for Medical Oncology (ESMO) Congress! Year after year, we attend key congresses to observe the latest cutting-edge data presentations that pave the way for a better tomorrow. Being immersed in the live event allows us to not only take in the content, but to be part of many customer conversations that we can translate into meaningful implications for our clients in real time. If you're heading to Barcelona, reach out to the team on the ground Sami Hocine, PhD, Nikil D. Kumar, Eleanor (Tyler) Maughan, PhD, Amanda Eckel, Ian Purcell, Camila Prieto, PhD, Robert Wickham to learn more about our networking events. We hope to see you there! #oncexperts #globalagency #ESMO2024

September is National Sickle Cell Awareness Month, and we are passionate about shining a light on how we can all shape the future of this disease! Our experts got together to discuss their vision for the future of disease diagnosis, treatment, and patient management. As you'll hear, there is still a lot to be done, and we're dedicated to advancing this space. Click below and join Denise (Minton) Lee-Thorp, Linda Beach, Ph.D., Marie Jones, and Angela Nurse as they share perspective that ranges from deep scientific expertise to personal experience.

Last week, here on LinkedIn, you met Juan M. Valdez Capuccino, Ph.D. as he walked the halls of the annual Alzheimer's Association International Conference in Philly as one of BGB Group's distinguished neurology experts. Today, in partnership with Exene Anderson, PhD and our Kx Advisors colleagues Chris Waybill, Adriana González-Caballero, and Chloe Weiser, Juan is digging a bit deeper into one of the topics that came up - blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM

Our BGB Group colleagues Juan M. Valdez Capuccino, Ph.D., Gina Marrone PhD Susan Duffy, and Kx Advisors partners Nikil D. Kumar and Chris Waybill spent the last week in Philly at the Alzheimer's Association International Conference taking in the latest data on diagnosis, treatment, and disease management. In such a complex space, it's topics like emerging targets and how blood based biomarkers will inform treatment decisions that have our experts excited. We'll share more on these topics in the coming days. Reach out to learn more about what we took away from AAIC and our perspective on the future of AD!